Jon Congleton - 12 Jan 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MLYS
Reported as of: 12 Jan 2026
Net transaction value: -$529,640
SEC form: 4
Accepted by SEC: 13 Jan 2026, 20:43:42 UTC
Prior SEC filing: 24 Nov 2025
Next SEC filing: 20 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Levy, Attorney-in-fact

Key filing fact

Jon Congleton filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 13 Jan 2026.

Key facts

This page summarizes Jon Congleton's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 13 Jan 2026, 20:43.

Change

Previous filing in this sequence was filed on 24 Nov 2025.
Current net transaction value: -$529,640.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001644975 Primary reporting owner

Congleton Jon

Relationship: Chief Executive Officer, Director
Address: 150 N. RADNOR CHESTER RD., SUITE F200, RADNOR
Signature: /s/ Adam Levy, Attorney-in-fact
Signature date: 13 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLYS transaction

Common Stock

Sale

Transaction value: $293,707
Shares: -9,119
Change %: -1.4%
Price: $32.21
Shares after: 646,268
Date: 12 Jan 2026
Ownership: Direct
Footnotes: F1, F2

MLYS transaction

Common Stock

Sale

Transaction value: $235,932
Shares: -7,117
Change %: -1.1%
Price: $33.15
Shares after: 639,151
Date: 12 Jan 2026
Ownership: Direct
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on January 28, 2025.

Footnote F2

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.8400 to $32.8028. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Footnote F3

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.8439 to $33.5000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.